The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the
development of lipid nanoparticle delivery systems that not only efficiently express the …

The world raced to develop vaccines to protect against the rapid spread of SARS-CoV-2
infection upon the recognition of COVID-19 as a global pandemic. A broad spectrum of …

To elicit optimal immune responses, messenger RNA vaccines require intracellular delivery
of the mRNA and the careful use of adjuvants. Here we report a multiply adjuvanted mRNA …

The triumphant success of mRNA vaccines is a testimony to the important role drug delivery
technologies have played in protecting billions of people against SARS-CoV-2 (or the …

Vaccines based on mRNA-containing lipid nanoparticles (LNPs) pioneered by Katalin
Karikó and Drew Weissman at the University of Pennsylvania are a promising new vaccine …

Vaccination represents the best line of defense against infectious diseases and is crucial in
curtailing pandemic spread of emerging pathogens to which a population has limited …

mRNA Lipid nanoparticles (LNPs) have recently been propelled onto the center stage of
therapeutic platforms due to the success of the SARS-CoV-2 mRNA LNP vaccines (mRNA …

There has been increased interest in the development of RNA-based vaccines for protection
against various infectious diseases and also for cancer immunotherapies. Rapid and cost …

Messenger RNA (mRNA) has emerged as a new category of therapeutic agent to prevent
and treat various diseases. To function in vivo, mRNA requires safe, effective and stable …

Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …